Ivosidenib Oral Tablet

DRUG3 trials

Sponsors

Servier Affaires Médicales, Servier Bio-Innovation LLC, PETHEMA Foundation

Conditions

Acute Myeloid Leukemia With Gene MutationsCholangiocarcinomaIDH1-Mutated Malignancies

Phase 1

A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment

RecruitingNCT07006688

Servier Bio-Innovation LLCIDH1-Mutated Malignancies

Start: 2026-01-14End: 2028-08-31Target: 30Updated: 2026-08-06

Phase 2

Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

RecruitingNCT07507760

PETHEMA FoundationAcute Myeloid Leukemia With Gene Mutations

Start: 2026-06-12End: 2029-04-01Target: 50Updated: 2026-09-02

Phase 3

An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma

Active, not recruitingNCT05876754

Servier Affaires MédicalesCholangiocarcinoma

Start: 2023-05-03End: 2027-12-01Updated: 2026-07-31

Related Papers

Real-world and randomized clinical trial comparison in patients with m <i>IDH1</i> CCA treated with ivosidenib: ProvIDHe vs ClarIDHy.

Journal of Clinical Oncology2026-05-28